Study Supports Delay of CDK4/6 Inhibitors Until Second-Line Treatment in Advanced HR+/HER2- Breast Cancer

被引：0
作者：
Rugo, Hope S. [1 ]
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2023年 / 21卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：352 / 353
页数：2
相关论文
共 50 条
  • [31] Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2-Metastatic Breast Cancer in Postmenopausal Women in the USA
    Masurkar, Prajakta P.
    Damgacioglu, Haluk
    Deshmukh, Ashish A.
    Trivedi, Meghana V.
    PHARMACOECONOMICS, 2023, 41 (06) : 709 - 718
  • [32] Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil
    Queiroz, Marcello Moro
    Sacardo, Karina Perez
    Ribeiro, Mauricio Fernando
    Gadotti, Luiza Lara
    Saddi, Rodrigo
    Oliveira, Leandro Jonata de Carvalho
    Linck, Rudinei Diogo Marques
    Cruz, Marcelo Rocha de Souza
    Barroso-Sousa, Romualdo
    Sahade, Marina
    Correa, Tatiana Strava
    Mano, Max Senna
    Suzuki, Daniele Assad
    Shimada, Andrea Kazumi
    Katz, Artur
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2023, 35
  • [33] Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA
    Prajakta P. Masurkar
    Haluk Damgacioglu
    Ashish A. Deshmukh
    Meghana V. Trivedi
    PharmacoEconomics, 2023, 41 : 709 - 718
  • [34] Cellular senescence in the response of HR+ breast cancer to radiotherapy and CDK4/6 inhibitors
    Klapp, Vanessa
    Buque, Aitziber
    Bloy, Norma
    Sato, Ai
    Yamazaki, Takahiro
    Zhou, Xi Kathy
    Formenti, Silvia C.
    Galluzzi, Lorenzo
    Petroni, Giulia
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
  • [35] Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2-breast cancer
    Wu, Sijia
    Xu, Junnan
    Ma, Yiwen
    Liang, Guilian
    Wang, Jiaxing
    Sun, Tao
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [36] Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2-breast cancer: an umbrella review
    Pu, Dongqing
    Xu, Debo
    Wu, Yue
    Chen, Hanhan
    Shi, Guangxi
    Feng, Dandan
    Zhang, Mengdi
    Liu, Zhiyong
    Li, Jingwei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (01)
  • [37] Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2-Metastatic Breast Cancer
    Goyal, Ravi K.
    Candrilli, Sean D.
    Abughosh, Susan
    Chen, Hua
    Holmes, Holly M.
    Johnson, Michael L.
    CANCERS, 2024, 16 (12)
  • [38] Cellular senescence in the response of HR+ breast cancer to radiotherapy and CDK4/6 inhibitors
    Vanessa Klapp
    Aitziber Buqué
    Norma Bloy
    Ai Sato
    Takahiro Yamazaki
    Xi Kathy Zhou
    Silvia C. Formenti
    Lorenzo Galluzzi
    Giulia Petroni
    Journal of Translational Medicine, 21
  • [39] Real-world experience with CDK4/6 inhibitors for HR+/HER2-metastatic breast cancer (MBC)
    Abdallah, H. M. A.
    Owoseni, Y. I.
    Sultan, A.
    Ahmed, S.
    Wood, J.
    Varadhan, B.
    Ayodele, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S369 - S370
  • [40] Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2-metastatic breast cancer
    Zagami, Paola
    Esposito, Angela
    Salimbeni, Beatrice Taurelli
    Giachetti, Pier Paolo Maria Berton
    Scafetta, Roberta
    Lambertini, Matteo
    Di Maio, Massimo
    Curigliano, Giuseppe
    Criscitiello, Carmen
    Cinieri, Saverio
    BREAST, 2025, 79
12345